Clinical Trial Update: 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) [Phase 2]

View source ↗

Summary

A Phase 2 trial of 90Y DOTA/Retinoic Acid for neuroblastoma and neuroendocrine tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Neuroendocrine Tumor

Drugs mentioned

• 90Y DOTA/Retinoic Acid

Snippet

Sponsor: University of Iowa | Conditions: Neuroblastoma, Neuroendocrine Tumor | Phase 2 | Status: WITHDRAWN